Ptc Therapeutics (PTCT) Change in Receivables (2012 - 2026)

Ptc Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $19.7 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 190.08% year-over-year to $19.7 million; the TTM figure through Jun 2026 stood at $44.4 million (up 720.58% YoY), while the FY2025 annual figure was $10.2 million, up 686.09% from the prior year.
• Change in Receivables for Q2 2026 stood at $19.7 million, down from $40.4 million in the prior quarter.
• The five-year high for Change in Receivables was $47.8 million in Q1 2025, with the low at -$40.8 million in Q4 2024.
• The 5-year median for Change in Receivables is $3.8 million (2022), against an average of $6.6 million.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables sank 2258.37% in 2023, then soared 194.89% in 2024.
• Ptc Therapeutics' Change in Receivables stood at $23.7 million in 2022, then sank by 135.23% to -$8.3 million in 2023, then tumbled by 388.27% to -$40.8 million in 2024, then surged by 45.5% to -$22.2 million in 2025, then surged by 188.81% to $19.7 million in 2026.
• Business Quant data shows PTCT's Change in Receivables at $19.7 million in Q2 2026, $40.4 million in Q1 2026, and -$22.2 million in Q4 2025.